Glaucoma medication adherence and glaucoma-related distress were both improved when patients used the Support, Educate, Empower (SEE) glaucoma coaching program vs the standard written education ...
The federal IACC, created in 2006, provides nonbinding guidance that helps align national autism research and services and supports coordination of approximately $2 billion in annual government ...
From innovative therapies to global care strategies, HIV experts at CROI 2026 share the breakthroughs and lessons they hope every viewer, near or far, takes home.
From innovative therapies to global care strategies, HIV experts at CROI 2026 share the breakthroughs and lessons they hope every viewer, near or far, takes home.
Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
A retrospective registry analysis linked ischemic and hemorrhagic strokes to pollutant levels on the event day and prior two days to reflect delayed physiologic effects. Ozone spikes (peak 136 ppb vs ...
Despite these declines, CRC incidence is rising in adults younger than 65, increasing by 3% per year among patients aged 20 to 49 years and 0.4% per year among those aged 50 to 64 years. Consequently, ...
The gap in shared decision-making was similarly notable. Clinicians rated their own effectiveness in involving patients at 80.8 out of 100, while patients rated clinician involvement at only 69.1.
Povorcitinib 75 mg achieved high-threshold lesion clearance by week 12, including 100% draining-tunnel reduction in 12%–57% and total abscess clearance in 22%–62% of participants. Phase 3 data show ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after one ARPI and delayed chemotherapy.
Advanced practice providers expand access by conducting initial consults, ordering diagnostic workups, explaining anti-amyloid risk–benefit tradeoffs, and coordinating multidisciplinary stakeholders ...
Vaccine development remains central to reducing incident HIV globally, particularly where long-acting PrEP access is limited, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results